Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...
MUNICH, Germany I January 30, 2025 I Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing ...
Immunome's varegacestat is in a phase 3 trial in patients with desmoid tumors that should produce results in H2'25. Read why ...
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
GlobalData on MSN1d
FDA expands Enhertu approval to include HER2-ultralow breast cancer patientsEnhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...
OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials: A Phase 1a/1b clinical trial for patients with solid tumors (NCT04892342). A Phase 3 study in ...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced the launch of its TrailBlazer™ Tag and TrailBlazer StarBright™ Dye Label Kits.
Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...
The agency approved the drug based on data from the DESTINY-Breast06 trial, which included patients who had tumors with very low HER2 expression.
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...
The artificial intelligence community is raving over a new reasoning model that has surprised even Silicon Valley.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback